Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

May 29, 2020

Chugai Files Patent Infringement Lawsuit concerning Edirol Capsules against Sawai and Nichi-Iko

Name of listed company: Chugai Pharmaceutical Co., Ltd.
Code number: 4519 (1st Section of Tokyo Stock Exchange)
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo
Chairman & CEO: Tatsuro Kosaka
Inquiries to: Masahiko Uchida,
Head of Corporate Communications Dept.
Tel:+81-(0)3-3273-0881

Chugai Pharmaceutical Co., Ltd. announced today that it has filed a patent infringement lawsuit with the Tokyo District Court and has also filed a petition for provisional disposition order, demanding the suspension of manufacturing and distribution of the generic drugs of an osteoporosis agent, active vitamin D3 derivative Edirol® Capsule 0.5µg / 0.75µg (generic name: eldecalcitol, hereafter, Edirol Capsule), against Sawai Pharmaceutical Co., Ltd. and Nichi-Iko Pharmaceutical Co., Ltd., the marketing authorization holders of generic versions of the drug, citing such parties’ infringement of a use patent owned by Chugai and Taisho Pharmaceutical Co., Ltd.

  1. Date of Complaint
    May 29, 2020
  2. Reasons for the Action
    On February 17, 2020, Sawai and Nichi-Iko received approval from the Ministry of Health, Labour and Welfare for their generic drugs of Edirol Capsule, respectively. Chugai and Taisho currently co-market Edirol Capsule wherein Chugai alleged that the generic drugs of Edirol Capsule infringe both companies’ use patent (patent number 5969161) , and filed an injunction with the Tokyo District Court against the manufacture, transfer, import, and offer of any transfer regarding the generic drugs, and disposal of stock.
  3. Defendants
    1. Name: Sawai Pharmaceutical Co., Ltd.
      Address: 5-2-30, Miyahara, Yodogawa-ku, Osaka, Japan
    2. Name: Nichi-Iko Pharmaceutical Co., Ltd.
      Address: 1-6-21 Sogawa, Toyama City, Toyama Prefecture, Japan
  4. Prospects
    No changes are expected to Chugai’s financial prospects at this point.

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top